[go: up one dir, main page]

GB2292887A - Drug delivery system - Google Patents

Drug delivery system

Info

Publication number
GB2292887A
GB2292887A GB9523475A GB9523475A GB2292887A GB 2292887 A GB2292887 A GB 2292887A GB 9523475 A GB9523475 A GB 9523475A GB 9523475 A GB9523475 A GB 9523475A GB 2292887 A GB2292887 A GB 2292887A
Authority
GB
United Kingdom
Prior art keywords
delivery system
drug delivery
lectin
active agent
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9523475A
Other versions
GB2292887B (en
GB9523475D0 (en
Inventor
John David Smart
David John Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PORTSMOUTH ENTERPRISE, University of
Original Assignee
PORTSMOUTH ENTERPRISE, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939307904A external-priority patent/GB9307904D0/en
Priority claimed from GB939324682A external-priority patent/GB9324682D0/en
Application filed by PORTSMOUTH ENTERPRISE, University of filed Critical PORTSMOUTH ENTERPRISE, University of
Priority to GB9523475A priority Critical patent/GB2292887B/en
Publication of GB9523475D0 publication Critical patent/GB9523475D0/en
Publication of GB2292887A publication Critical patent/GB2292887A/en
Application granted granted Critical
Publication of GB2292887B publication Critical patent/GB2292887B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A drug delivery system is provided which comprises a lectin and a pharmacologically active agent in which the active agent is releasably bound to the lectin. The lectin has been found to selectively attach to glycoproteins e.g. within the cornea of the eye, thereby enabling a drug to be selectively delivered thereto.
GB9523475A 1993-04-16 1994-04-15 Drug delivery system Expired - Fee Related GB2292887B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9523475A GB2292887B (en) 1993-04-16 1994-04-15 Drug delivery system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939307904A GB9307904D0 (en) 1993-04-16 1993-04-16 Drug delivery system
GB939324682A GB9324682D0 (en) 1993-12-01 1993-12-01 Drug delivery system
PCT/GB1994/000806 WO1994023752A1 (en) 1993-04-16 1994-04-15 Drug delivery system
GB9523475A GB2292887B (en) 1993-04-16 1994-04-15 Drug delivery system

Publications (3)

Publication Number Publication Date
GB9523475D0 GB9523475D0 (en) 1996-01-17
GB2292887A true GB2292887A (en) 1996-03-13
GB2292887B GB2292887B (en) 1997-05-07

Family

ID=26302771

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9523475A Expired - Fee Related GB2292887B (en) 1993-04-16 1994-04-15 Drug delivery system

Country Status (3)

Country Link
AU (1) AU6510094A (en)
GB (1) GB2292887B (en)
WO (1) WO1994023752A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001600A1 (en) * 1995-05-30 2002-01-03 Michael J. Oldham Method of using lectins for prevention and treatment of skin diseases and disorders
WO1997005267A2 (en) * 1995-07-26 1997-02-13 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
GB0213383D0 (en) * 2002-06-11 2002-07-24 Cambridge Biotechnology Ltd Therapeutic conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000076A1 (en) * 1991-06-24 1993-01-07 Minnesota Mining And Manufacturing Company Carrier systems for drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000076A1 (en) * 1991-06-24 1993-01-07 Minnesota Mining And Manufacturing Company Carrier systems for drugs

Also Published As

Publication number Publication date
GB2292887B (en) 1997-05-07
AU6510094A (en) 1994-11-08
GB9523475D0 (en) 1996-01-17
WO1994023752A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
PL312193A1 (en) Intravaginal administration device
CA2181742A1 (en) Reduction of skin irritation during electrotransport delivery
TW370532B (en) The use of cetrorelix and other nona and decapeptides in the preparation of a medicament for combating AIDS and for growth stimulation
MY124695A (en) Novel composition and use.
EE9700286A (en) Controlled release of miotic and mydriatic drugs in the anterior chamber of the eye
ID28003A (en) ADAMANTANA'S DEMONS
IL127510A0 (en) A therapeutic conjugate
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
GR3026338T3 (en) High release solid preparation, preparation and use thereof
PH31652A (en) Dihydrolipoic acid as ophthalmological agent to suppress intolerable reactions in the aea between implants and living body tissue.
HU904007D0 (en) Medical preparations providing regulated active agent discharge and processes for the preparation thereof
GB2292887A (en) Drug delivery system
EP1563862A3 (en) Needleless syringe
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
AU6901191A (en) Pharmacologically active substance bpc, the process for its preparation and its use in the therapy
AU5386700A (en) A use of icariin in preparing the medicine for preventing and treating sexual disorder and vasoconstrictive diseases
CA2193405A1 (en) Eyewash intended in particular for the treatment of the dry eye syndrome
ZA933086B (en) Novel method of treatment of Parkinson's disease
ATE60231T1 (en) INSOLUBLE DRUG DELIVERED LOCALLY IN THE EAR.
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
EP0676206A4 (en)
ES2070090A1 (en) Integral protector for the spinal column
Grahner From Germany-China Association
AU6843596A (en) In vitro model for study of the pharmacodynamics of intracellular killing of bacteria and viruses

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20080415